---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-114665"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-11-02T12:39:46+00:00"
generated_at: "2026-11-02T12:45:08.377077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.62
calibrated_materiality_score: 0.62
confidence: "high"
source: SEC EDGAR
---

# CorMedix reaffirms 2026 revenue guidance of $325-345M; CMS sets Q1 2027 DefenCath Add-on at $8.32 per session

## Summary
- Unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026; full Q3 results to be discussed on a November 12, 2026 call.
- Reaffirmed August 2026 full-year 2026 total revenue guidance of $325 million to $345 million.
- CMS's October 28, 2026 ESRD PPS final rule set the Q1 2027 DefenCath post-TDAPA Add-on at $8.32 per dialysis session, 3.5x the current $2.37 rate.
- CorMedix expects the Add-on to decline in Q2 2027 versus Q1, then rise in Q3 and/or Q4, with the full-year 2027 average above 2x the current $2.37.
- Company said it provided no utilization or pricing data to any large dialysis organization; third-party 2027 Add-on projections are not CorMedix guidance.

## SEC filing metadata
- accession: 0001213900-26-114665
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-11-02T12:39:46+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.62
- calibrated_materiality_score: 0.62
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390026114665/0001213900-26-114665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390026114665/ea0310445-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-114665
- JSON: https://secwatch.observer/filing/0001213900-26-114665.json
- Plain text: https://secwatch.observer/filing/0001213900-26-114665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.